Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLXNASDAQ:ELVNNYSE:OGNNASDAQ:RNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$62.44-7.1%$66.76$47.88▼$107.37$3.43B0.32539,918 shs645,744 shsELVNEnliven Therapeutics$20.03+0.9%$21.10$15.96▼$30.03$973.22M1.03277,713 shs468,707 shsOGNOrganon & Co.$14.42-2.1%$15.22$13.87▼$23.10$3.72B0.762.55 million shs3.05 million shsRNAAvidity Biosciences$28.10-5.6%$31.41$21.56▼$56.00$3.38B1.021.36 million shs2.26 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx-7.12%-8.86%-4.86%-21.09%-1.20%ELVNEnliven Therapeutics+0.86%-6.88%+0.55%-17.98%+7.75%OGNOrganon & Co.-2.19%-1.02%+0.85%-6.63%-19.50%RNAAvidity Biosciences-5.61%-13.70%-1.61%-7.87%+5.48%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACLXArcellx2.0184 of 5 stars3.61.00.00.03.02.50.0ELVNEnliven Therapeutics2.7264 of 5 stars3.61.00.00.03.84.20.0OGNOrganon & Co.4.7018 of 5 stars3.21.03.33.72.91.73.1RNAAvidity Biosciences2.5592 of 5 stars4.51.00.00.03.80.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 3.14Buy$110.6777.24% UpsideELVNEnliven Therapeutics 3.20Buy$38.7593.46% UpsideOGNOrganon & Co. 2.43Hold$20.8044.27% UpsideRNAAvidity Biosciences 3.00Buy$66.69137.34% UpsideCurrent Analyst Ratings BreakdownLatest ELVN, RNA, ACLX, and OGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$37.00 ➝ $39.003/17/2025RNAAvidity BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.003/17/2025RNAAvidity BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00 ➝ $72.003/17/2025RNAAvidity BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$65.00 ➝ $65.003/13/2025RNAAvidity BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$70.003/12/2025RNAAvidity BiosciencesBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$72.003/10/2025RNAAvidity BiosciencesBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $48.003/7/2025RNAAvidity BiosciencesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$70.002/28/2025RNAAvidity BiosciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$63.00 ➝ $57.002/28/2025RNAAvidity BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$65.00 ➝ $65.002/14/2025OGNOrganon & Co.BarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$26.00 ➝ $24.00(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$107.94M31.78N/AN/A$9.97 per share6.26ELVNEnliven TherapeuticsN/AN/AN/AN/A$5.97 per shareN/AOGNOrganon & Co.$6.40B0.58$4.62 per share3.12($0.27) per share-53.40RNAAvidity Biosciences$10.90M309.99N/AN/A$6.76 per share4.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$70.69M-$2.00N/AN/AN/A-25.94%-8.28%-5.21%5/8/2025 (Estimated)ELVNEnliven Therapeutics-$71.58M-$1.89N/AN/AN/AN/A-29.46%-27.33%5/13/2025 (Estimated)OGNOrganon & Co.$864M$3.334.333.850.9013.49%431.62%8.03%5/1/2025 (Estimated)RNAAvidity Biosciences-$212.22M-$2.89N/AN/AN/A-2,772.45%-27.66%-24.56%5/8/2025 (Estimated)Latest ELVN, RNA, ACLX, and OGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025N/AOGNOrganon & Co.$0.92N/AN/AN/A$1.53 billionN/A3/13/2025Q4 2024ELVNEnliven Therapeutics-$0.53-$0.46+$0.07-$0.46N/A$0.03 million2/27/2025Q4 2024ACLXArcellx-$0.63-$0.87-$0.24-$0.87$27.42 million$15.27 million2/27/2025Q4 2024RNAAvidity Biosciences-$0.76-$0.80-$0.04-$0.80$1.74 million$2.97 million2/13/2025Q4 2024OGNOrganon & Co.$0.92$0.83-$0.09$0.42$1.57 billion$1.59 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/AOGNOrganon & Co.$1.127.77%+25.99%33.63%N/ARNAAvidity BiosciencesN/AN/AN/AN/AN/ALatest ELVN, RNA, ACLX, and OGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/13/2025OGNOrganon & Co.quarterly$0.287.3%2/24/20252/24/20253/13/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A4.294.29ELVNEnliven TherapeuticsN/A17.4417.44OGNOrganon & Co.17.731.701.21RNAAvidity BiosciencesN/A17.7617.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%ELVNEnliven Therapeutics95.08%OGNOrganon & Co.77.43%RNAAvidity BiosciencesN/AInsider OwnershipCompanyInsider OwnershipACLXArcellx6.24%ELVNEnliven Therapeutics29.20%OGNOrganon & Co.1.40%RNAAvidity Biosciences3.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8054.94 million50.70 millionOptionableELVNEnliven Therapeutics5049.00 million34.59 millionOptionableOGNOrganon & Co.10,000257.95 million253.93 millionNot OptionableRNAAvidity Biosciences190120.21 million114.92 millionOptionableELVN, RNA, ACLX, and OGN HeadlinesRecent News About These CompaniesKathleen P. Gallagher Sells 5,875 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockApril 4 at 5:52 AM | insidertrades.comAvidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?April 3 at 10:35 AM | zacks.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Bought by Wellington Management Group LLPApril 3 at 5:04 AM | marketbeat.comWhy Avidity Biosciences, Inc.’s (RNA) Stock Is Up 11.33%April 3 at 2:53 AM | aaii.comAvidity Biosciences completes enrollment in Phase 1/2 Fortitude trialApril 2 at 1:35 PM | markets.businessinsider.comPictet Asset Management Holding SA Increases Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)April 2 at 4:31 AM | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Shares Down 7% - Time to Sell?April 1 at 2:00 PM | marketbeat.comAvidity Biosciences to Participate in Upcoming Investor ConferenceApril 1 at 9:00 AM | prnewswire.comAvidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular DystrophyMarch 31, 2025 | prnewswire.comArtisan Partners Limited Partnership Sells 314,028 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)March 30, 2025 | marketbeat.com9,534 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Acquired by Quantbot Technologies LPMarch 30, 2025 | marketbeat.comNatixis Advisors LLC Makes New Investment in Avidity Biosciences, Inc. (NASDAQ:RNA)March 28, 2025 | marketbeat.comThe Risk/Reward Of Avidity Biosciences And Its 2 Promising ProgramsMarch 26, 2025 | seekingalpha.comHow Is Avidity Biosciences Inc. (NASDAQ:RNA) Positioned in the Biotech Sector?March 26, 2025 | kalkinemedia.comEFG Asset Management North America Corp. Increases Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA)March 26, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Trading 8.5% Higher - Time to Buy?March 25, 2025 | marketbeat.comCibc World Markets Corp Acquires New Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)March 25, 2025 | marketbeat.comSwiss National Bank Acquires 18,800 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)March 25, 2025 | marketbeat.com198,907 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Bought by Raymond James Financial Inc.March 25, 2025 | marketbeat.comMagnetar Financial LLC Acquires Shares of 22,003 Avidity Biosciences, Inc. (NASDAQ:RNA)March 23, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) CFO Sells $246,461.10 in StockMarch 22, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesSuper Micro's International Presence Makes It a Winning StockBy Gabriel Osorio-Mazilli | March 17, 2025View Super Micro's International Presence Makes It a Winning Stock3 Tech Stocks Defying Sector Weakness and Thriving in 2025By Leo Miller | March 10, 2025View 3 Tech Stocks Defying Sector Weakness and Thriving in 2025How to Build the Ultimate Everything ETF PortfolioBy Jeffrey Neal Johnson | March 16, 2025View How to Build the Ultimate Everything ETF PortfolioModerna: 4 Key Reasons the CEO Just Bought $5M in SharesBy Jea Yu | March 11, 2025View Moderna: 4 Key Reasons the CEO Just Bought $5M in SharesDisney Stock: 4 Key Metrics Validating Its ComebackBy Jea Yu | March 17, 2025View Disney Stock: 4 Key Metrics Validating Its ComebackELVN, RNA, ACLX, and OGN Company DescriptionsArcellx NASDAQ:ACLX$62.44 -4.79 (-7.12%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$62.82 +0.38 (+0.61%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Enliven Therapeutics NASDAQ:ELVN$20.03 +0.17 (+0.86%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$21.32 +1.29 (+6.46%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Organon & Co. NYSE:OGN$14.42 -0.30 (-2.06%) Closing price 04/3/2025 03:58 PM EasternExtended Trading$14.12 -0.29 (-2.03%) As of 08:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Avidity Biosciences NASDAQ:RNA$28.10 -1.67 (-5.61%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$28.02 -0.08 (-0.28%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Celsius Heats Up: Acquisition, Analyst Upgrade Fuel Momentum 5 Reasons Why Halliburton Is a Good Buy in 2025 First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock Tesla Stock: What To Expect With Their Delivery Numbers Report Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future Equinix: A Smart Bet on Data Centers, Dividends, and AI Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
